Skip to main content

Table 3 Histomorphometric data for femur

From: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

Group

Control (n = 12)

Fenofibrate (n = 11)

Pioglitazone (n = 8)

Trabecular bone

Volume (%)

22.2 ± 5.95

21.70 ± 5.72

16.3 ± 1.38**/#

Total area

(mm2)

6.34 ± 0.40

6.35 ± 0.23

6.61 ± 0.30

Cortical area

(mm2)

3.99 ± 0.29

4.18 ± 0.16

4.05 ± 0.21

Medullary area

(mm2)

2.35 ± 0.25

2.18 ± 0.11*

2.56 ± 0.16###

  1. Data is presented as mean ± SD. *P<0.05, **P < 0.01 significantly different compared to control. #P < 0.05, ###P < 0.001 significantly different compared to fenofibrate-treated group.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us